What is WO2010020675A1 about, and how does it relate to ribociclib?
WO2010020675A1 is a patent publication tied to the chemical/pharmaceutical inventions underlying CDK4/6 inhibitor development. Ribociclib (a CDK4/6 kinase inhibitor used in hormone receptor–positive, HER2-negative breast cancer) belongs to the same therapeutic area, so patent families covering specific substituted compounds, preparation methods, and related intermediates can be relevant to ribociclib’s broader intellectual-property landscape.
However, the specific connection depends on what claims in WO2010020675A1 cover (for example: whether it claims the exact ribociclib chemical structure, a close analog, a key intermediate used in synthesis, or a general method for making that class of compounds).
How can you check whether this patent claims the ribociclib molecule itself?
To determine whether WO2010020675A1 directly covers ribociclib, you typically look for these items inside the publication:
- The described chemical structures and examples, and whether ribociclib’s structure appears verbatim in the claims or examples.
- Claim scope language (for example, whether it is limited to a narrow set of substitutions that match ribociclib, or written more broadly for a class).
- Named intermediates and synthetic steps that match known ribociclib manufacturing routes.
If you share the ribociclib-specific context you have (for example, claim number(s), an intermediate name, or a screenshot of the compound table), I can help interpret what that implies about coverage.
Who is likely to hold or use this patent in the ribociclib space?
CDK4/6 inhibitors were developed by multiple companies over time, and patent ownership differs by compound vs. manufacturing process vs. specific jurisdictions. Without the publication’s bibliographic data (assignee/applicant and inventors), it’s hard to state which company controls WO2010020675A1 for ribociclib-related rights.
If you provide the assignee listed on WO2010020675A1, I can help connect it to the ribociclib ecosystem (originator vs. later challengers) and typical freedom-to-operate considerations.
How does this affect generic or biosimilar entry for ribociclib?
For small-molecule oncology drugs like ribociclib, the practical impact of a patent like WO2010020675A1 usually shows up through:
- Patent term and patent family coverage across countries (not just the WO publication).
- Whether national-stage equivalents were granted and where.
- Whether the patent is a “compound” patent (often strongest) versus a “process/intermediate” patent (may still block certain manufacturing or force design-around).
To evaluate entry risk, you would compare:
- WO publication date / priority date (controls the basic timeline),
- which jurisdictions it entered and was granted,
- and whether any later patent challenges or litigation narrowed the enforceable scope.
Where can you find reliable ribociclib patent listings and timelines?
A useful place to cross-check ribociclib patents, including family links and (where available) expiration or exclusivity context, is DrugPatentWatch.com. Start with the ribociclib page on that site and then match listed families back to WO2010020675A1.
Source: DrugPatentWatch ribociclib page (use to locate the relevant patent family and jurisdictions): https://www.drugpatentwatch.com/
What I need from you to give a precise “this claims ribociclib / not” answer
Paste any of the following from WO2010020675A1 and I’ll map it directly to ribociclib:
- the assignee/applicant name,
- the claim text (especially independent claims),
- an example compound table row (with structure or name),
- or the publication’s “Field of Invention” and “Claims” section headings.
Sources
- https://www.drugpatentwatch.com/